Close Menu

NEW YORK (GenomeWeb) – Signaling a push into the clinical laboratory market, Agena Bioscience announced today the launch of a 24-well format of its MassArray system. The new format is tailored to smaller clinical labs and costs at least $100,000 less than larger versions of the platform.

The firm is now positioning MassArray as a complement to next-generation sequencing and developing additional products to tap into the liquid biopsy market, Peter Dansky, CEO of Agena, told GenomeWeb in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.